TOG 2020-2021 YAYINLAR LİSTESİ

1: NazimTurhal S, Dogan M, Esendagli G, Artac M, Korkmaz L, Coskun HS, Goker E, PerranYumuk F, Bilgetekin I, Kose F, Uncu D, Kavgaci H, Akyol G, Ozet A, Yagci

  1. The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study. J Gastrointest Cancer. 2021 Mar 3. doi: 10.1007/s12029-021-00602-4. Epub ahead of print. PMID: 33656690.

 

2: Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C,Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Çınkır HY, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş M, Karaoğlan M, Şenler FÇ. Trastuzumab ± Capecitabine Maintenance After the First- Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. J Gastrointest Cancer.

2021 Feb 4. doi: 10.1007/s12029-021-00594-1. Epub ahead of print. PMID: 33538958.

 

3: Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C,

Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal

NS, Üskent N, Yeşil Çınkır H, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş

M, Karaoğlan M, Çay Şenler F. Combination of trastuzumab and taxane-containing

intensified chemotherapy in first-line treatment of HER2-positive advanced

gastric cancer. Tumori. 2020 Nov 9:300891620969823. doi:

10.1177/0300891620969823. Epub ahead of print. PMID: 33167790.

 

4: Türkkan G, Alkan A, Paydaş S, Tanrıverdi Ö, Karakaş Y, Karadurmuş N, Sakin A,

Temiz S, Arpacı E, Akın M, Menekşe S, Şen CA, Barışta İ. Demographical and

Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish

Oncology Group (TOG). Indian J Hematol Blood Transfus. 2020 Oct;36(4):640-645.

doi: 10.1007/s12288-020-01257-0. Epub 2020 Feb 22. PMID: 33100705; PMCID:

PMC7573056.

 

5: Beypinar I, Demir H, Sakin A, Taskoylu BY, Sakalar T, Ergun Y, Korkmaz M,

Ates O, Eren T, Turhal S, Artac M. The Real-Life Data of BRAF Mutation on the

Treatment of Colorectal Cancer: a TOG Study. J Gastrointest Cancer. 2020 Sep 11.

doi: 10.1007/s12029-020-00514-9. Epub ahead of print. PMID: 32914373.

 

6: Alkan A, Yaşar A, Güç ZG, Gürbüz M, Başoğlu T, Sezgin Göksu S, Buğdaycı Başal

F, Türk HM, Özdemir Ö, Yeşil Çınkır H, Güven DC, Kuş T, Türker S, Koral L,

Karakaş Y, Ak N, Paydaş S, Karcı E, Demiray AG, Demir A, Alan Ö, Keskin Ö, Nayır

E, Tanrıverdi Ö, Yavuzşen T, Yumuk PF, Ateş Ö, Coşkun HŞ, Turhal S, Çay Şenler

  1. Worse patient-physician relationship is associated with more fear of cancer

recurrence (Deimos Study): A study of the Palliative Care Working Committee of

the Turkish Oncology Group (TOG). Eur J Cancer Care (Engl). 2020

Nov;29(6):e13296. doi: 10.1111/ecc.13296. Epub 2020 Aug 30. PMID: 32864838.

 

7: Yildiz B, Kucukarda A, Gokyer A, Gokcen Demiray A, Paydas S, Pinar Aral I,

Gumusay O, Bilici A, Akdeniz N, Bahceci A, Demir H, Esin E, Üyeturk U, Nihat

Okten I, Erturk I, Turk HM, Topaloglu US, Basoglu T, Serdar Turhal N, Yesil

Cinkir H, Menekse S, Cakmak Y, Urun Y, Acar R, Kut E, Dal P, Sakalar T, Halit

Aktepe O, Karadurmus N, Bilici A. Does primary tumor localization has prognostic

importance in seminoma patients?: Turkish Oncology Group Study. J BUON. 2020

Mar-Apr;25(2):1130-1135. PMID: 32521916.

 

8: Ergen SA, Dincbas FO, Yücel B, Altınok P, Akyurek S, Korkmaz Kıraklı E, Ulger

S, Etiz D, Yilmaz U, Kılıc D, Bozcuk H. Risk factors of radiation pneumonitis in

patients with NSCLC treated with concomitant chemoradiotherapy–Are we

underestimating diabetes?–Turkish oncology group (TOG)/Lung cancer study group.

Clin Respir J. 2020 Sep;14(9):871-879. doi: 10.1111/crj.13220. Epub 2020 Jun 23.

PMID: 32470205.

 

9: Hizal M, Sendur MA, Yasar HA, Bir Yucel K, Arslan C, Ucar G, Karakaya S,

Taban H, Kucukarda A, Erturk I, Bilgin B, Yıldırım N, Demirci U, Kılıckap S,

Cicin I, Karadurmus N, Yalcin B, Ürün Y. Neutrophil-lymphocyte ratio as a

prognostic factor for survival in patients with advanced renal cell carcinoma

(Turkish Oncology Group Study). J Oncol Pharm Pract. 2020 Oct;26(7):1583-1589.

doi: 10.1177/1078155219900908. Epub 2020 Feb 13. PMID: 32054412.

 

10:  Arzu Yaşar H, Turna H, Esin E, Murat Sedef A, Alkan A, Oksuzoglu B, Ozdemir

N, Sendur MN, Sezer A, Kılıckap S, Utkan G, Akbulut H, Celik I, Abalı H, Urun Y.

Prognostic factors for survival in patients with mucosal and ocular melanoma

treated with ipilimumab: Turkish Oncology Group study. J Oncol Pharm Pract. 2020

Mar;26(2):267-272. doi: 10.1177/1078155219840796. Epub 2019 Mar 29. PMID: